BIOCRYST PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $8.03 per share for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2023-02-27
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2014-03-31 was $8.11, a 801.11% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2013-03-31 was $0.90, a 73.29% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2012-03-31 was $3.37.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $8.03, a 142.60% increase from fiscal 2021.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $3.31, a 29.42% decline from fiscal 2020.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $4.69, a 81.78% increase from fiscal 2019.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $2.58, a 47.56% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | $8.03 10-K · filed 2023-02-27 | ||||||
| 2021-12-31 | $3.31 10-K · filed 2022-02-28 | ||||||
| 2020-12-31 | $4.69 10-K · filed 2021-03-01 | ||||||
| 2019-12-31 | $2.58 10-K · filed 2020-03-13 | ||||||
| 2018-12-31 | $4.92 10-K · filed 2019-03-14 | ||||||
| 2017-12-31 | $3.63 10-K · filed 2018-03-12 | ||||||
| 2016-12-31 | $2.17 10-K · filed 2017-02-27 | ||||||
| 2015-12-31 | $7.72 10-K · filed 2016-02-26 | ||||||
| 2014-09-30 | $8.19 10-Q · filed 2014-11-07 | ||||||
| 2014-03-31 | $8.11 10-Q · filed 2014-08-08 | $8.28 10-Q · filed 2014-05-09 | |||||
| 2013-12-31 | $7.76 10-K · filed 2015-03-02 | $1.28 10-K · filed 2014-03-10 | |||||
| 2013-09-30 | $2.10 10-Q · filed 2014-11-07 | ||||||
| 2013-06-30 | $0.90 10-Q · filed 2013-08-08 | ||||||
| 2013-03-31 | $0.90 10-Q · filed 2014-08-08 | $0.88 10-Q · filed 2013-05-09 | |||||
| 2012-12-31 | $3.24 10-K · filed 2014-03-10 | ||||||
| 2012-09-30 | $3.24 10-Q · filed 2013-11-08 | ||||||
| 2012-06-30 | $3.04 10-Q · filed 2013-08-08 | $3.37 10-Q · filed 2012-08-08 | |||||
| 2012-03-31 | $3.37 10-Q · filed 2013-05-09 | ||||||
| 2011-12-31 | $2.64 10-K · filed 2014-03-10 | ||||||
| 2011-09-30 | $2.75 10-Q · filed 2012-11-08 | ||||||
| 2011-06-30 | $2.75 10-Q · filed 2012-08-08 | ||||||
| 2010-12-31 | $4.65 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |